Clinical Trials
58 trialsNCT07505615 2026-04-01
VG-INFUSE Tria
Fudan University
Phase 1/2 Completed
NCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT05223491 2026-01-16
En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer
Aarhus University Hospital
Phase NA Completed
NCT07347132 2026-01-16
Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder Tumor
Lahore General Hospital
Phase NA Completed
NCT05375903 2026-01-14
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 1 Completed
NCT04897763 2026-01-07
PERTINENCE
Institut Cancerologie de l'Ouest
Phase EARLY_PHASE1 Completed
NCT03914794 2025-10-03
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03081858 2025-06-27
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
Phase 1/2 Completed
NCT06818799 2025-02-12
Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer
Helwan University
Phase NA Completed
NCT01697306 2025-01-30
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
Phase 2 Completed
NCT05085977 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT05085990 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT06767982 2025-01-10
Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)
Ankara University
Phase 4 Completed
NCT04387461 2024-09-25
CORE-001
CG Oncology, Inc.
Phase 2 Completed
NCT04593862 2024-09-19
BRAVE
University of Alberta
Phase 2 Completed
NCT05136898 2024-09-19
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 3 Completed
NCT02773849 2024-07-29
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Ferring Pharmaceuticals
Phase 3 Completed
NCT03636256 2023-08-14
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Phase 1/2 Completed
NCT02449239 2023-07-24
VISTA
Sesen Bio, Inc.
Phase 3 Completed
NCT03191578 2023-07-14
RUTIVAC-1
Archivel Farma S.L.
Phase 1 Completed
NCT04311580 2023-06-22
Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure
University of Rome Tor Vergata
Phase 2 Completed
NCT02695771 2023-04-21
BIC
Corewell Health West
Phase 3 Completed
NCT02371447 2023-04-13
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
Swiss Cancer Institute
Phase 1/2 Completed
NCT03854721 2023-03-03
A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer
Vaxiion Therapeutics
Phase 1 Completed
NCT03558503 2022-09-16
OPTIMA II
UroGen Pharma Ltd.
Phase 2 Completed
NCT02316171 2022-07-27
CANON
Viralytics
Phase 1 Completed
NCT00318643 2021-10-29
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
Halozyme Therapeutics
Phase 1/2 Completed
NCT02009332 2021-06-08
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Aadi Bioscience, Inc.
Phase 1/2 Completed
NCT04885309 2021-05-13
Efficacy and Safety of Obturator Nerve Block During Transurethral Resection on Non-muscle Invasive Intermediate and High Risk Lateral Wall Bladder Tumours
Ankara Training and Research Hospital
Phase NA Completed
NCT04498702 2020-08-13
Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Phase 2 Completed
NCT03672240 2020-07-20
NMIBC
AsierisPharma
Phase 1/2 Completed
NCT03715660 2019-11-21
Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study
Mansoura University
Phase NA Completed
NCT00595088 2019-04-30
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Anchiano Therapeutics Israel Ltd.
Phase 2 Completed
NCT03053635 2018-08-20
Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
Theralase® Technologies Inc.
Phase 1 Completed
NCT02560584 2018-07-02
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Photocure
Phase 3 Completed
NCT02214602 2018-03-22
NMIBCIVT
Mansoura University
Phase 4 Completed
NCT01004211 2018-01-17
Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Phase NA Completed
NCT02852564 2017-08-22
Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection
University of Kansas Medical Center
Phase 1 Completed
NCT01687244 2017-07-24
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
FKD Therapies Oy
Phase 2 Completed
NCT01803295 2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA Completed
NCT02307487 2017-06-16
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
Phase 2 Completed
NCT02891460 2016-09-08
Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients
UroGen Pharma Ltd.
Phase NA Completed
NCT00734994 2015-06-29
Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
Duke University
Phase EARLY_PHASE1 Completed
NCT02207608 2015-05-28
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
University of Rome Tor Vergata
Phase 2 Completed
NCT02007005 2015-05-06
Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
Abnoba Gmbh
Phase 1/2 Completed
NCT01731652 2015-02-10
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Telormedix SA
Phase 2 Completed
NCT01498172 2015-02-04
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
University of Lausanne Hospitals
Phase 1 Completed
NCT02343614 2015-01-22
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Phase 2 Completed
NCT01939756 2013-09-11
Baobab
University of Rome Tor Vergata
Phase 1/2 Completed
NCT01920269 2013-08-09
EMDA/MMC
University of Rome Tor Vergata
Phase 2/3 Completed